As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: September 9, 2012
by Dementia Today:
Data from people with a rare form of early-onset Alzheimer’s disease offer a detailed look at each ominous step of the descent into severe Alzheimer’s dementia.
Only 1% of people with Alzheimer’s disease get the early-onset form. But the new findings strongly suggest that the relentless progression of Alzheimer’s disease is the same in patients with the much more common “sporadic” form of the illness.
“A series of changes begins in the brain decades before the symptoms of Alzheimer’s disease are noticed by patients or families,” study leader Randall Bateman, MD, of Washington University, said in a news release. “This cascade of events may provide a timeline for symptom onset.”
To get this timeline, Bateman and colleagues in the Dominantly Inherited Alzheimer’s Network (DIAN) studied 128 people who inherited one of the three gene mutations that doom a person to early Alzheimer’s disease.
Each generation carrying the mutation gets full-blown Alzheimer’s dementia at about the same age. So the DIAN team used the age of symptom onset in participants’ parents to estimate when they, too, would have full-blown Alzheimer’s. In this study that was about age 46, give or take seven years.
Timeline of Alzheimer’s Disease
The findings reveal the dramatic timeline of Alzheimer’s disease:
“These exciting findings are the first to confirm what we have long suspected — that disease onset begins years before the first sign of cognitive decline or memory loss,” Laurie Ryan, PhD, of the National Institute on Aging, says in a news release. The DIAN study is largely funded by the National Institutes of Health.
The new data suggest that even in age-related Alzheimer’s disease, the disease timeline depends less on a person’s age than on the time when the disease process begins.
The findings also suggest that targeting beta-amyloid early in the disease process may be more helpful than waiting until a patient starts to develop symptoms of mental decline.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.